Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$13.95
Change (%) Stock is Up 0.25 (1.82%)
Volume372,584
Data as of 05/23/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
05/23/18Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
05/16/18Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
05/11/18Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
04/17/18Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
Upcoming EventsMore >>
DateTitle
06/14/18
through
06/17/18
Eiger BioPharmaceuticals at the ISVHLD Global Hepatitis Summit
LocationToronto, Canada
06/22/18
through
06/26/18
Eiger BioPharmaceuticals at the American Diabetes Association
08/14/18
through
08/15/18
Eiger BioPharmaceuticals at the Wedbush PacGrow Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.